Merck Reports Five-Year KEYNOTE-189 Data for Keytruda in Non-Squamous NSCLC

Merck today presented five-year overall survival data from the Phase 3 KEYNOTE-189 trial evaluating Keytruda (pembrolizumab) plus pemetrexed and platinum chemotherapy in patients with previously untreated metastatic non-squamous non-small cell lung cancer. The data showed that 19.4% of patients in the Keytruda arm were alive at five years compared to 11.3% in the placebo arm.